Pulmonary, Critical Care, and Sleep Medicine

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Compare Transverse Diagnostic Methods in Pediatric Patients After Polysomnogram for Diagnosis of Obstructive Sleep Apnea

   Rochester, Minn.

   The primary purpose of this study is to analyze maxillary transverse dimensions in children who have completed polysomnography (PSG), using McNamara’s Criteria and Andrew’s Six Elements.

2. A Dose Escalation Study of JNJ-61186372 in Participants With Advanced Non-Small Cell Lung Cancer

   Rochester, Minn.

   The purpose of this study is to evaluate the safety and pharmacokinetics, establish a recommended phase 2 dose (RP2D) regimen, and to assess the preliminary effectiveness of JNJ-61186372 in participants with advanced non-small cell lung cancer (NSCLC).

3. Real Time Detection of Electrophysiologic Disturbances Following Subdural Hematoma Evacuation

   Rochester, Minn.

   The purpose of this study is to detect and characterizer electrophysiologic disturbances (such as local field potentials) in patients with underrecognized cause of coma, focal deficits and prolonged encephalopathy following subdural hematoma (SDH) evacuation.

4. Impulse Oscillometry in Idiopathic Subglottic StenosisCap

   Rochester, Minn.

   The purpose of this study is to describe impulse oscillometry (IOS) in patients with symptomatic idiopathic subglottic stenosis (iSGS). The study will also compare IOS findings in patients with iSGS with IOS findings in patients with small airways obstruction and in healthy controls.

    

5. COVID-19 and Acute Renal Failure

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The primary purpose of this study is to examine 1-year survival and rate of secondary infections in COVID-19 patients with and without acute kidney injury (AKI).

    

    

    

6. COVID-19 Remote Monitoring

   Jacksonville, Fla.

   As a part of the COVID-19 pandemic, Mayo Clinic Florida is utilizing remote monitoring technology to monitor non-ICU patients in order to identify patients who will need the ICU and prevent crashing patients on the floor. MCF is using approved InTouch video and Biofourmis remote vital sign monitoring technology, both used by Mayo Clinic in other capacities. This study will not be a study of the efficacy or the accuracy of these devices as they are already incorporated as standard of practice. This study will assess the reduction of on floor crashing patients, quality of care, and satisfaction of providers by using this technology.  

7. Treating Sleep Apnea Induced Hypoxemia With Oxygen in Acute Stroke Patients

   Rochester, Minn.

   We want to determine if treating acute ischemic stroke patients who have evidence of hypoxemia due to sleep apnea with low flow O2 during sleep might help improve clinical and functional outcomes.

8. Effectiveness and Safety of Pembrolizumab for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer

   Jacksonville, Fla., Rochester, Minn.

   This trial will evaluate the safety and effectiveness of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], followed by pembrolizumab alone after surgery [adjuvant phase] in participants with resectable stage IIB or IIIA non-small cell lung cancer (NSCLC).

9. A Study to Evaluate Whether or Not Selexipag is Effective and Safe in Patients with Chronic Thromboembolic Pulmonary Hypertension when the Disease is Inoperable or Persistent/Recurrent After Surgery

   Jacksonville, Fla.

   The primary objective of this study is to evaluate the effect of selexipag on pulmonary vascular resistance (PVR) versus placebo in subjects with inoperable CTEPH (i.e., technically non-operable) and persistent/recurrent CTEPH after surgical (pulmonary endarterectomy [PEA]) and/or interventional (balloon pulmonary angioplasty [BPA] treatment at Week 20.
   
   The secondary objectives are to evaluate the effects of selexipag versus placebo on exercise capacity, rate of death or hospitalizations related to Pulmonary Hypertension (PH) worsening, time to clinical worsening, WHO functional class (FC), patient reported outcomes, dyspnea, and N-terminal pro b-type natriuretic peptide (NT-proBNP).

10. Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

    Rochester, Minn.

    The purpose of this clinical trial is to determine if low dose naltrexone is effective in improving health-related quality of life (HRQoL) among patients with vasculitis. Although it is a pilot study, a placebo-controlled component is used because of the prominent placebo group effect seen in studies with self-reported subjective outcomes.

    Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication. There are a few scientific studies in three conditions (fibromyalgia, Crohn's disease, and multiple sclerosis) that suggest that this drug has benefit and is safe. However, considering the extent of use in other conditions, and uncertainty about the mechanism of action study is needed in a diverse set of diseases, including vasculitis.